The aim of the paper is to study the contributions of evidence-based medicine to the awareness, placement and usage of medicines for the treatment of the most important allergic disorders in recent years. In Cochrane studies, various antiasthmatic medicines were reassessed for their effectiveness and medication interactions. In 2017 the Evaluation-based Medicine (EBM) Recommendations for Allergic Rhinitis and its Effect on Asthma (ARIAs) have been reworded and innovative healthcare point instruments have over these years been contributing to aligning the guidelines with real life by extracting input from patients themselves to finely model pharmacological suggestions. Lastly, recent systematic analyses helped rely on best-suited comparison results with the goal of responding promptly as new medications were developed for the treatment of peanut allergy.
In the last two years, EBM has helped to modify the GINA Recommendations. It played a role in the real world of the ARIA guidelines. It has also helped shape the promise and drawbacks of immunotherapy with oral peanuts. EBM is a tremendous tool for advancing awareness of allergy medicine.
